| Previous Close | 1.80 |
| Open | 1.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 1.76 - 1.98 |
| 52 Week Range | 0.65 - 2.50 |
| Volume | 7,989 |
| Avg. Volume | 5,590 |
| Market Cap | 7.42M |
| Beta | 0.17 |
| PE Ratio (TTM) | 115.62 |
| EPS (TTM) | 0.02 |
| Earnings Date | Nov 14, 2017 - Nov 20, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.54 |
- GlobeNewswire•3 days ago
International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial
CARLSBAD, Calif., Sept. 20, 2017-- International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced ...
Capital Cube•5 days agoInternational Stem Cell Corp. :ISCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
Categories: Yahoo FinanceGet free summary analysis International Stem Cell Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of International Stem Cell Corp. – Keryx Biopharmaceuticals, Inc., Opexa Therapeutics, Inc., Celgene Corporation, Anthera Pharmaceuticals, Inc., Chimerix, Inc. and Vericel Corporation (KERX-US, OPXA-US, CELG-US, ANTH-US, CMRX-US and ... Read more (Read more...)
- GlobeNewswire•16 days ago
International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease
CARLSBAD, Calif., Sept. 07, 2017-- International Stem Cell Corporation, a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today reported ...
